A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

• Documented initial diagnosis of multiple myeloma according to International MyelomaWorking Group (IMWG) diagnostic criteria

• Measurable disease at Screening

• Received at least 3 prior lines of treatment for multiple myeloma a) Undergone at least 1 complete cycle of treatment for each line, unlessprogressive disease (PD) was documented by IMWG criteria as the best response to theregimen

• Received a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)

• Participant must have documented evidence of progressive disease based oninvestigator's determination of response consistent with IMWG criteria on or within 12 months of their last regimen. Non-responsive disease is defined as either failureto achieve minimal response or development of progressive disease (PD) while ontherapy. Also, participants with documented evidence of PD disease (as above) withinthe previous 6 months and who are refractory or non-responsive to their most recentline of treatment afterwards are eligible

• Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1

Exclusion Criteria:

• Prior treatment with chimeric antigen receptor T (cells) CAR-T therapy directed atany target

• Any therapy that is targeted to B-cell maturation antigen (BCMA)

• The following cardiac conditions: a) New York Heart Association (NYHA) stage III orIV congestive heart failure b) Myocardial infarction or coronary artery bypass graft (CABG) 6 months prior to enrollment c) History of clinically significant ventriculararrhythmia or unexplained syncope, not believed to be vasovagal in nature or due todehydration d) History of severe non-ischemic cardiomyopathy e) Impaired cardiacfunction (left ventricular ejection fraction [LVEF] less than [<]45%) as assessed byechocardiogram or multiple-gated acquisition (MUGA) scan (performed less than orequal to (<=) 8 weeks of apheresis)

• Have received a cumulative dose of corticosteroids equivalent to greater than orequal to(>=)70 milligram (mg) of prednisone within 7 days prior to apheresis

• Diagnosed or treated for invasive malignancy other than multiple myeloma, except:

1. Malignancy treated with curative intent and with no known active diseasepresent for greater than or equal to (>=) 2 years before enrollment; or

2. Adequately treated non-melanoma skin cancer without evidence of disease

• Prior antitumor therapy with insufficient washout period

• Toxicity from previous anticancer therapy must resolve to baseline levels or toGrade 1 or less except for alopecia or peripheral neuropathy

• Received either of the following:

1. An allogeneic stem cell transplant for multiple myeloma

2. An autologous stem cell transplant less than or equal to (<=) 12 weeks beforeapheresis

• Known active, or prior history of, central nervous system (CNS) involvement orexhibits clinical signs of meningeal involvement of multiple myeloma